이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

성인의 둔부 피부 이완 개선에 있어 Juläine™의 안전성과 성능을 평가하기 위한 전향적 임상 연구.

2026년 11월 10일 업데이트: Nordberg Medical AB

성인의 둔부 피부 이완 개선을 위한 Poly-L-lactic Acid - Juläine™의 안전성과 성능 평가를 위한 전향적 임상 연구.

This study aims to evaluate the safety and effectiveness of Juläine™ (poly-L-lactic acid) injections for the treatment of buttock skin laxity.

Participants will be randomized to an immediate-treatment group or a delayed-treatment group. The immediate-treatment group will receive 2 to 3 treatment sessions over up to 2 months and will be compared with the delayed-treatment group during the control period; the delayed-treatment group will receive the same treatment after the delay.

The primary objective is to assess clinical improvement in buttock skin elasticity 6 months after the last treatment, defined as an increase in skin elasticity measured by a cutometer. Total study participation is up to 16 months, including follow-up.

This multicenter trial will be conducted in Brazil.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

This is an pivotal, open-label, two-arm, randomized, parallel-group, prospective clinical investigation conducted in Brazil to evaluate the safety and effectiveness of Juläine™ (poly-L-lactic acid) administered as subcutaneous injections for the treatment skin laxity in the buttock (gluteal) region in adults.

A total of 100 participants will be randomized to either an immediate-treatment group or a delayed-treatment group (delayed-start control). Participants in the immediate-treatment group will receive Juläine™ subcutaneous injections in 2 or 3 sessions at Day 0, Day 30, and Day 60. During this initial control period, outcomes in the immediate-treatment group will be compared with those in the delayed-treatment group, which will not receive treatment. After the control period, participants in the delayed-treatment group will receive the same Juläine™ regimen at Day 240, Day 270, and Day 300. Each participant will remain in the study for up to 16 months, excluding screening.

The primary efficacy endpoint is improvement in buttock skin elasticity 6 months after the last injection defined as an increase in global skin elasticity measured by a cutometer, with assessments at screening/baseline and at the primary post-treatment timepoint. The mean change in global skin elasticity measured by cutometer and Global Aesthetic Improvement Scale (GAIS) will also be evaluated, comparing groups during the control period.

Safety will be monitored through the collection of adverse events (AEs) through 240 days after randomization, with comparisons between groups during the control period. Adverse events will also be evaluated through extended follow-up, including up to 180 days in the overall study population and up to 480 days in the immediate-treatment group.

연구 유형

중재적

등록 (추정된)

100

단계

  • 해당 없음

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Adults aged 18 to 55 years;
  • Body Mass Index (BMI) between 18.5 and 24.95 kg/m².
  • Skin laxity of the gluteal region defined as sagging and reduced tightness of the skin.
  • Women of childbearing potential must be willing to abide by the contraceptive requirements
  • Ability to understand the study and provide informed consent, attend follow-up visits, and follow post-injection instructions.

Exclusion Criteria:

  • Pregnancy or breastfeeding, or planned pregnancy/lack of adequate contraception (through 8 weeks post-study);
  • Is planning to donate/bank or retrieve eggs (ova, oocytes) or donate sperm during the study or within 8-weeks of the end of participation of the clinical investigation.
  • Active infection, inflammation or lesions at or near the treatment site.
  • Acute infection at screening;
  • History of autoimmune disease;
  • Immune deficiencies;
  • History of hypertrophic scarring or keloid formation;
  • History of thrombosis in the lower limbs.
  • Previous surgical procedures involving the buttocks
  • Previous treatment with fillers, suspension threads, or fat injection in the treatment area within 18 months before randomization.
  • Previous aesthetic procedures in the treatment area, including radiofrequency, ultrasound, cryotherapy, neurotoxin, laser or light treatment, or chemical peel, within six months before randomization.
  • Previous topical or home therapy for cellulite in the treatment area within three months before randomization.
  • Hemorrhagic disease or ongoing use of antiplatelets/anticoagulant therapy.
  • Treatment with chemotherapy, immunosuppressive agents, systemic corticosteroids within 3 months before treatment (inhaled or ophthalmic corticosteroids are allowed).
  • Use of hormonal replacement therapy (HRT) unless the participant has been on a stable dose for at least 3 months prior to screening and does not plan to make any changes to the HRT regimen during the study period.
  • Use of topical corticosteroids, topical prescription retinoids in the treatment area within 1 month of the Baseline visit or systemic retinoid treatment within 6 months of the baseline visit, or plan to receive such treatment.
  • Use of other agents that inhibit collagen production.
  • Known allergy or hypersensitivity to any component of the investigational product.
  • History of herpes simplex rashes, malignant skin diseases, or any other serious dermatologic or systemic disease.
  • Presence of any condition that may impair wound healing (e.g., connective tissue disorders, severe malnutrition).
  • Planned or ongoing cosmetic procedures involving the buttocks or surrounding area during the period of clinical investigation.
  • Presence of any skin or local condition in the treatment area that could interfere with treatment administration, participant safety, or evaluation of study endpoints, including scars, fibrosis, tattoos, skin-pigmentation alterations, inflammation, lymphedema, or lipedema.
  • Participants actively taking GLP-1 medications with the intention of achieving additional weight loss (expected >10% during study) will be excluded. Participants on a stable GLP-1 regimen (≥3 months) for diabetes management or weight maintenance, with documented weight stability (±10% in past 6 months) and no planned or expected weight change >10%, may be included.
  • Any other medical or psychological condition that, in the opinion of the investigator, may interfere with participation in clinical research or evaluation of results.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 즉시-치료 그룹

Juläine™ is a sterile injectable medical device composed of polylactic acid microspheres.

다른: 지연-치료군 (지연 시작 대조군)

Juläine™ is a sterile injectable medical device composed of polylactic acid microspheres.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Proportion of participants who achieve an improvement in gluteal skin elasticity
기간: Baseline and 240 days after randomization

Proportion of participants achieving a clinically significant reduction in gluteal skin laxity at Day 240 after randomization, whereby a clinically significant reduction ("response") is defined as a relative increase of at least 10% in the gross elasticity measured by cutometer at Day 240 compared to baseline.

Baseline and 240 days after randomization

2차 결과 측정

결과 측정
측정값 설명
기간
Mean change in overall skin elasticity
기간: Baseline and Day 240 after randomization.

Mean change in global medial skin elasticity measured by cutometer 180 days after treatment completion.

Baseline and Day 240 after randomization.
Global improvement based on Global Aesthetic Improvement Scale (GAIS) evaluated by investigator
기간: Baseline and Day 240 after randomization.

Proportion of participants with at least a 1-point improvement in GAIS as rated by the investigator at Day 240 after randomization.

The GAIS scale values are:

  1. Very much improved
  2. Much improved
  3. Improved
  4. No change
  5. Worse

Where 1 represents the best outcome and 5 represents the worst.

Baseline and Day 240 after randomization.
Global improvement based on Global Aesthetic Improvement Scale (GAIS) evaluated by participant
기간: Baseline and Day 240 after randomization.

Proportion of participants with at least a 1-point improvement in GAIS as rated by the participant at Day 240 after randomization

The GAIS scale values are:

  1. Very much improved
  2. Much improved
  3. Improved
  4. No change
  5. Worse

Where 1 represents the best outcome and 5 represents the worst.

Baseline and Day 240 after randomization.
Proportion of adverse events (AEs)
기간: Occurring up to 240 days after the start of treatment, in both groups.

Proportion of adverse events (AEs) occurring up to 240 days after randomization.

Occurring up to 240 days after the start of treatment, in both groups.
Incidence and severity of Adverse events in the first 30 days
기간: First 30 days after each Juläine™ administration, in all treated participants.

Incidence and severity of Adverse events in the first 30 days after each Juläine™ administration, in all treated participants.

First 30 days after each Juläine™ administration, in all treated participants.
Incidence and severity of AEs up to 240 days.
기간: Up to 240 days after start of treatment in all treated participants.

Incidence and severity of AEs up to 240 days after start of treatment in all treated participants.

Up to 240 days after start of treatment in all treated participants.
Incidence and severity of AEs up to 480 days
기간: Up to 480 days after start of treatment in the immediate-start group.

Incidence and severity of AEs up to 480 days after start of treatment in the immediate-start group.

Up to 480 days after start of treatment in the immediate-start group.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2027년 6월 1일

기본 완료 (추정된)

2028년 1월 1일

연구 완료 (추정된)

2029년 1월 1일

연구 등록 날짜

최초 제출

2025년 12월 30일

QC 기준을 충족하는 최초 제출

2025년 12월 30일

처음 게시됨 (실제)

2026년 1월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 3월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • NB 15-TF-BZ-100-08F

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .